MediciNova, Inc MNOV shares soared 111% in the regular and after-hours sessions on Tuesday.
What Happened: The biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas.
BARDA, under a program aimed to repurpose drugs in response to chemical threats, will provide funding for proof-of-concept studies of MN-166 in preclinical models of chlorine gas-induced acute lung injury.
“MN-166 has the potential to improve health outcomes and save lives. To date, more than 800 research participants have been treated with high-dose MN-166 in MediciNova’s clinical trials. MN-166 has shown a benign safety and tolerability profile,” said Kazuko Matsuda, Chief Medical Officer at MediciNova.
See also: Best Healthcare Stocks Right Now
Why It Matters: MN-166 is the first compound to receive development support through the BARDA program.
Last week, the company announced it was discontinuing the development of a vaccine for COVID-19 in order to “maintain adequate resources for its other development programs.”
Price Action: MediciNova shares rose 105.11% to $11.65 in after-hours trading on Tuesday after closing 5.97% higher at $5.68.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
